Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) EBITDA (2016 - 2026)

Integra Lifesciences Holdings' EBITDA history spans 17 years, with the latest figure at $23.0 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 35.33% to $23.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$496.1 million, a 99325.65% decrease, with the full-year FY2025 number at -$493.4 million, down 1836.55% from a year prior.
  • EBITDA hit $23.0 million in Q4 2025 for Integra Lifesciences Holdings, up from -$6.5 million in the prior quarter.
  • Over the last five years, EBITDA for IART hit a ceiling of $75.8 million in Q1 2021 and a floor of -$490.9 million in Q2 2025.
  • Historically, EBITDA has averaged $1.1 million across 5 years, with a median of $25.9 million in 2021.
  • Biggest five-year swings in EBITDA: surged 2523.84% in 2021 and later tumbled 2296.61% in 2025.
  • Tracing IART's EBITDA over 5 years: stood at $58.2 million in 2021, then grew by 16.52% to $67.8 million in 2022, then tumbled by 46.86% to $36.0 million in 2023, then fell by 1.17% to $35.6 million in 2024, then tumbled by 35.33% to $23.0 million in 2025.
  • Business Quant data shows EBITDA for IART at $23.0 million in Q4 2025, -$6.5 million in Q3 2025, and -$490.9 million in Q2 2025.